Literature DB >> 18789119

Extracorporeal photopheresis normalizes some lymphocyte subsets (including T regulatory cells) in chronic graft-versus-host-disease.

John Bladon1, Peter Taylor.   

Abstract

Extracorporeal photopheresis (ECP) has been demonstrated to be clinically effective for the treatment of steroid-refractory graft-versus-host-disease (GvHD). Recently, a murine model suggested that ECP may modulate the allo-reactivity, seen in GvHD, by enhancement of T regulatory cells. T regulatory cells are an important component of immune tolerance and reduced levels of them have been observed in chronic GvHD. Samples were taken from eight chronic GvHD patients prior to receiving any ECP therapy and after three months of ECP. Samples were also obtained from eight age- and sex-matched normal controls. Each sample was evaluated for absolute levels of total lymphocytes and CD4(+) and CD8(+) T cells. T regulatory cell numbers were also assessed accordingly: CD4(+)CD25(high), CD4(+)CD25(high)CD69(-), CD4(+)CD25(high)CD152(+) and CD4(+)CD25(high)FOXP3(+). Following three months of ECP, increases in the absolute counts of total lymphocytes, CD4(+) and CD8(+) T cells and T regulatory cells were observed; however, no selective statistical increase in the percentage of T regulatory cell numbers was observed within the CD4(+) T cell compartment. ECP induces an increase in T regulatory cell numbers; however, this is not specific as there is also an enhancement of both total lymphocyte and CD4(+) T cell numbers. The positive effect of ECP may therefore depend on a more generic re-adjustment of immune homeostasis.

Entities:  

Mesh:

Year:  2008        PMID: 18789119     DOI: 10.1111/j.1744-9987.2008.00593.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  7 in total

Review 1.  Extracorporeal Photopheresis: A Case of Immunotherapy Ahead of Its Time.

Authors:  Pablo Augusto Vieyra-Garcia; Peter Wolf
Journal:  Transfus Med Hemother       Date:  2020-05-27       Impact factor: 3.747

2.  Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation.

Authors:  Erin Gatza; Sung Won Choi
Journal:  Int J Hematol Oncol       Date:  2015-08

3.  Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP).

Authors:  Madan H Jagasia; Bipin N Savani; George Stricklin; Brian Engelhardt; Adetola Kassim; Sheri Dixon; Heidi Chen; Wichai Chinratanalab; Stacey Goodman; John P Greer; Friedrich Schuening
Journal:  Biol Blood Marrow Transplant       Date:  2009-08-03       Impact factor: 5.742

4.  Cyclosporine and Extracorporeal Photopheresis are Equipotent in Treating Severe Atopic Dermatitis: A Randomized Cross-Over Study Comparing Two Efficient Treatment Modalities.

Authors:  Uffe Koppelhus; Johan Poulsen; Niels Grunnet; Mette Søndergaard Deleuran; Erik Obitz
Journal:  Front Med (Lausanne)       Date:  2014-10-01

5.  Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients.

Authors:  Michael Thomas Burke; Lauren C Sambira Nahum; Nicole M Isbel; Robert P Carroll; Hans Peter Soyer; Ross Francis; Jennifer Anne Bridge; Carmel Hawley; Kimberly Oliver; Christine E Staatz; James William Wells
Journal:  Transplant Direct       Date:  2017-06-06

6.  Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation.

Authors:  Timothy J Brown; Cathy Gentry; Suntrea T G Hammer; Christine S Hwang; Madhuri Vusirikala; Prapti A Patel; Karén Matevosyan; Shannan R Tujios; Arjmand R Mufti; Robert H Collins
Journal:  ACG Case Rep J       Date:  2017-03-29

Review 7.  Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD).

Authors:  Matthew Mankarious; Nick C Matthews; John A Snowden; Arun Alfred
Journal:  Front Immunol       Date:  2020-01-31       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.